Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves’ Ophthalmopathy
- 20 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 45 (7) , 514-518
Abstract
Purpose The study aims to define the effect of different dose strategies on ophthalmic complications in patients with Graves' disease (GD). Methods All the patients with GD and no or inactive ophthalmopathy (clinical activity score; CAS < 3) underwent Snellen chart examination, measurement of proptosis, thyroid volume, and radioactive iodine uptake, and randomized into 1 of 3 groups. In group 1, all the patients received fixed low dose (FLD) of 259 MBq of(131)I, whereas in group 2, all the patients received fixed high dose (FHD) of 555 MBq, and in group 3, calculated dose (CD) was administered to deliver 5.55 MBq/g (thyroid weight) of(131)I. All examinations were repeated 6 months after treatment. The measurement of thyroid function tests and clinical examination were repeated after 12 months. Results We studied 92 patients (58 female and 34 male) with mean age of 38.2 +/- 12.0 years. Overall, 29, 32, and 31 patients were studied in FLD, FHD, and CD groups, respectively. The patients in CD received a mean activity of 240.5 MBq. The 3 groups were not significantly different regarding age, sex ratio, radioactive iodine uptake, smoking, visual acuity, and proptosis. The response rate 12 months after radioactive iodine therapy was 66.7%, 94.4%, and 92.9% in FLD, FHD, and CD groups, respectively (P= 0.05). Overall, CAS was increased significantly after treatment. Delta proptosis and delta CAS were increased significantly in FHD group compared with other groups (P< 0.05). The highest increment in proptosis was seen in FHD group. Conclusions The administration of 5.55 MBq/g of(131)I has fewer ophthalmic complications compared with high fixed dose model and is more effective than low fixed dose strategy.Keywords
This publication has 28 references indexed in Scilit:
- The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0Journal of Nuclear Medicine, 2012
- Graves' OphthalmopathyNew England Journal of Medicine, 2010
- Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysisEuropean Journal of Endocrinology, 2009
- Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review*Clinical Endocrinology, 2008
- Radioiodine Therapy and Graves' OphthalmopathyJournal of Nuclear Medicine, 2008
- Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GOEuropean Journal of Endocrinology, 2008
- Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologistsClinical Endocrinology, 2007
- Graves' Disease: A Long-Term Quality-of-Life Follow Up of Patients Randomized to Treatment with Antithyroid Drugs, Radioiodine, or SurgeryThyroid®, 2005
- Long‐term effects of radioiodine on thyrotrophin receptor antibodies in Graves' diseaseClinical Endocrinology, 1995
- EFFECT OF RADIOIODINE ON STIMULATORY ACTIVITY OF GRAVES’IMMUNOGLOBULINSClinical Endocrinology, 1982